SCHEMBL6629471

SCHEMBL6629471

O=C(CNC(=O)c1cc2scc(Cl)c2[nH]1)Nc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYGL P06737 1/20 0.55
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
PPARG P37231 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
DAO P14920 1/20 0.40
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
NSD2 O96028 1/20 0.39
PLA2G7 Q13093 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTPN11 Q06124 1/20 0.37
RHOC P08134 1/20 0.37
RHOA P61586 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6631163 0.84 PYGL (0.54) PYGLMEN1KMT2ADAOMAPT
SCHEMBL6630744 0.82 PYGL (0.54) PYGLPPARGNR2E3NCOR2
SCHEMBL6630570 0.78 PYGL (0.54) PYGLMEN1KMT2APPARGNR2E3
SCHEMBL6631404 0.76 NPC1 (0.53) PYGLMEN1KMT2AMAPTHTT
SCHEMBL6630734 0.74 PYGL (0.54) PYGLMAPTL3MBTL1NPC1RAB9A
SCHEMBL6634840 0.73 NPC1 (0.56) PYGLMAPTHTTNPC1LMNA
SCHEMBL1243935 0.71 DAO (0.59) PYGLMEN1KMT2ADAOSMN1; SMN2
SCHEMBL6630267 0.70 PYGL (0.46) PYGLPPARGNR2E3NCOR2
SCHEMBL6629961 0.70 PYGL (0.49) PYGLNPC1RAB9ASMN1; SMN2
SCHEMBL2106879 0.70 PYGL (0.50) PYGLNPC1LMNARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317459-B1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2004-04-07 EP claimed
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2003-12-18 US claimed
EP-1317459-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS AstraZeneca AB (SE) 2003-06-11 EP claimed
WO-2002020530-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2002-03-14 WO claimed
EP-1317459-B1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2004-04-07 EP disclosed
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors GYS1, GYS2, PYGL PYGL 3/4885MEN1 4601/4885KMT2A 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.